Volnik Chemical Combine
 | This article is incomplete because it is pending further input from participants, or it is a work-in-progress by one author. Please comment on this article's talk page to share your input, comments and questions. Note: To contribute to this article, you may need to seek help from the author(s) of this page. |
| File:X | |
| Consortium | |
| Industry | chemicals, pharmaceuticals |
| Predecessor | Volnik Powderworks |
| Founded | 1898 |
| Founder | Zoltan Makloș (as Volnik Powderworks) |
| Headquarters | Ryșovsk , S.W.R. Strakosko, Ostrozava |
Area served | Worldwide |
Number of employees | 92,173 |
| Subsidiaries | Company One Company Two |
Volnik Chemical Combine (Ostro-Ludzic: Chemițký Kombinát Volník)) is a major Ostrozavan pharmaceutical and biotechnology consortium with its headquarters in Ryșovsk, in the subprime of Strakosko. Its portfolio of developments and products includes a variety of psychiatric drugs such as sertraline, panuramine, bupropion, and serdexmethylphenidate, among many others. Volnik is widely considered to have introduced the concept of the swallowable pill as opposed to the tincture to 1960s Ostrozavan society; they have since expanded to have international reach, having developed many pharmaceutical treatments for a wide variety of physical and mental disorders.
Initially founded as a smokeless powder factory in Ryșovsk in 1898, in the Empire of Transkarminia owned by the prominent Makloș family of Drevstranese Lushyod origin, the Volnik factory was nationalized following the 1922 Second Worker's Convetion. It continued producing gunpowder and other explosive substances, including hexogen and TNT, until after the Second Partisans' War, when it was demilitarized and denationalized by the Beranek administration. It then diversified beyond simple chemical production into the biopharmaceutical industry. Intially developing painkillers, it expanded to other products throughout the 1970s, providing breakthrough treatments for bipolar disorder and insomnia. In the 1980s, Volnik was one of the first market entities to produce and market antidepressant, antipsychotic, and antianxiety medication. When Primara Eva Sedlaková's administration began creating closer economic ties with Drevstran in the mid-1980s, Volnik entered into a lucrative partnership with well-established pharmaceutical companies, particularly Oldokem, for the procurement of raw chemicals and joint research on new compounds. Volnik has been considered "joined at the hip" with Oldokem to this day.
Since the 1960s, Volnik has been consistently expanding beyond its initial market with the accquisition of XXian company Company One in 1991 and XXese company Company Two in 2007; previously a simple cooperative, Volnik has since transitioned into a multinational consortium incorporating many smaller cooperatives, worker-enterprise-workshops, and corporations. Volnik has often been accused of fuelling the Ostrozavan mental health epidemic by marketing untested and potentially addictive or ineffective drugs liberally, and by intentionally downplaying the potentially harmful sideeffects of many of its products. Volnik has also recieved criticism due to its outsourcing of labor to avoid Ostrozavan worker protections, often garnering accusations of exploitation and underpayment.